---
title: "U.S. Stock Market Movement | Vaccine concept stocks show mixed performance, Novavax Pharmaceuticals rises by over 5.4%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/214306500.md"
description: "On Friday, vaccine concept stocks showed mixed performance, with Novavax Medicine seeing a rise in stock price, up over 5.4% to $12.57 as of press time. The company announced that its updated COVID-19 vaccine has been launched in the United States for the prevention of COVID-19 in individuals aged 12 and above. Moderna fell by nearly 4% to $66.92. Moderna plans to launch a mRNA-based skin cancer vaccine as early as next year. It is reported that Moderna has released mid-term data on its personalized cancer vaccine named mRNA-4157, which is used in combination with Merck's PD-1 therapy Keytruda for the treatment of melanoma. Pfizer saw a slight decrease of 0.22%"
datetime: "2024-09-13T15:10:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/214306500.md)
  - [en](https://longbridge.com/en/news/214306500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/214306500.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/214306500.md) | [English](https://longbridge.com/en/news/214306500.md)


# U.S. Stock Market Movement | Vaccine concept stocks show mixed performance, Novavax Pharmaceuticals rises by over 5.4%

According to the Wise Finance APP, on Friday, vaccine concept stocks showed mixed performance. Novavax (NVAX.US) saw its stock price rise, with an increase of over 5.4% to $12.57 as of the time of publication. The company announced that its updated COVID-19 vaccine has been launched in the United States for the prevention of COVID-19 in individuals aged 12 and above.

Moderna (MRNA.US) fell by nearly 4% to $66.92. Moderna plans to launch a mRNA-based skin cancer vaccine as early as next year. It is reported that Moderna has released mid-term data on its personalized cancer vaccine named mRNA-4157, which is combined with Merck's (MRK.US) PD-1 therapy Keytruda for the treatment of melanoma. Pfizer (PFE.US) saw a slight decrease of 0.22%

### 相關股票

- [Pfizer (PFE.US)](https://longbridge.com/zh-HK/quote/PFE.US.md)
- [Moderna (MRNA.US)](https://longbridge.com/zh-HK/quote/MRNA.US.md)
- [Novavax (NVAX.US)](https://longbridge.com/zh-HK/quote/NVAX.US.md)

## 相關資訊與研究

- [Komprise storage tiering service pledges flash savings](https://longbridge.com/zh-HK/news/280692430.md)
- [Guan Chao's Loss Balloons in 2025](https://longbridge.com/zh-HK/news/281314987.md)
- [Raymond James Financial Earnings Preview: What to Expect](https://longbridge.com/zh-HK/news/281024632.md)
- [GSK's Partner Shionogi Acquires Pfizer's Stake in ViiV Healthcare for About $2.13 Billion](https://longbridge.com/zh-HK/news/281346030.md)
- [Reeves’s stranglehold on the economy is tightening](https://longbridge.com/zh-HK/news/281316009.md)